Effect of ketamine combined with DHA on lipopolysaccharide-induced depression-like behavior in rats.
Daiyue Chang, Jinghua Zhao, Xintong Zhang, Huimin Lian, Xueman Du, Rui Yuan, Yajing Wen, Li Gao
International Immunopharmacology August 1, 2019 DOI: 10.1016/j.intimp.2019.105788 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Preclinical experimental study Peer reviewed |
|---|---|
| Population | Rats and PC12 cells |
| Interventions | Ketamine DHA |
| Topics | Depression Esketamine Ketamine |
| Key findings | Ketamine combined with DHA reversed lipopolysaccharide-induced depression-like behaviors and neuroinflammation in rats more effectively than either agent alone. |
Abstract
Depression has become a common mental illness, and studies have shown that neuroinflammation is associated with depression. Ketamine is a rapid antidepressant. In order to obtain better antidepressant effects, it is necessary to explore the efficacy of combination therapy with ketamine and other antidepressants. DHA is an unsaturated fatty acid with excellent application prospects due to its safety and antidepressant effects. This study was designed to investigate the effect of ketamine combined with DHA on lipopolysaccharide-induced depression-like behavior. In behavioral experiments, lipopolysaccharide prolongs the immobility time of the forced swimming and tail suspension tests in rats and reduces the sucrose preference. The combination of ketamine and DHA can reverse these changes and work better than the single application. Nissl staining showed that ketamine combined with DHA can reverse the nerve damage caused by lipopolysaccharide. Cell morphology observation the combination of ketamine and DHA group was more complete than that of LPS group. The combination of ketamine and DHA significantly decreased the levels of IL-1, IL-6 and TNF-ɑin hippocampus and PC12 cells and increased the content of BDNF. Immunofluorescence results showed that ketamine combined with DHA can effectively inhibit PP65 nuclear translocation. Western blot results showed that ketamine combined with DHA can effectively inhibit the expression of NF-KB in hippocampus and PC12 cells, and increase the expression of P-CREB and BDNF. In summary, the combination of ketamine with DHA may be a more effective treatment for depression caused by inflammation and is mediated by inhibition of the inflammatory pathway.
Comparable studies
Other preclinical and animal studies on ketamine for depression, most cited first.
Citations in the library
Cited by 4
- Ketamine’s effect on inflammation and kynurenine pathway in depression: A systematic review Journal of Psychopharmacology June 26, 2021
- Beating pain with psychedelics: Matter over mind? Neuroscience & Biobehavioral Reviews December 16, 2021
- Serum inflammatory cytokines in the progression of depression. Frontiers in Immunology 2026
- The Mechanisms Behind Rapid Antidepressant Effects of Ketamine: A Systematic Review With a Focus on Molecular Neuroplasticity Frontiers in Psychiatry April 25, 2022
Cites 5
- Synaptic Dysfunction in Depression: Potential Therapeutic Targets Science October 4, 2012
- NMDAR inhibition-independent antidepressant actions of ketamine metabolites Nature April 24, 2016
- Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial American Journal of Psychiatry August 28, 2013
- Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity. Drug Discovery Today February 6, 2016
- BDNF — a key transducer of antidepressant effects Neuropharmacology November 11, 2015